CCK-SAP References

Cat #IT-31

2018

Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu Z-W, Gao X-B, Kaelberer MM, Bohórquez DV, Shammah-Lagnado SJ, de Lartigue G, & de Araujo IE. A Neural Circuit for Gut-Induced Reward. (2018). Cell, 175 (3):665-678.

Objective:  To determine relevant gut-brain neuronal circuitry to motivational and emotional states.
Summary:  There is a critical role for the vagal gut-to-brain axis in motivation and reward.
Dose:  Injected 0.5 µl of CCK-SAP (250 ng/µl) into the R-NG of VGlut2-ires-Cre mice.

2017

Diepenbroek C, Quinn D, Stephens R, Zollinger B, Anderson S, Pan A, de Lartigue G. (2017) Validation and Characterization of a Novel Method for Selective Vagal Deafferentation of the Gut. Am J Physiol Gastrointest Liver Physiol 313(4):G342-52. PMID: 28705805

Objective:  To develop a new method that allows targeted lesioning of vagal afferent neurons that innervate the upper GI tract while sparing vagal efferent neurons.
Summary:  CCK-SAP ablates a subpopulation of VAN in culture. In vivo, CCK-SAP injection into the NG reduces VAN innervating the mucosal and muscular layers of the stomach and small intestine but not the colon, while leaving vagal efferent neurons intact.
DoseIn vitro: each well was treated with a different dose of saporin conjugates (0, 2.4, 24, or 240 ng) for 24 h.  In vivo: An equal volume (rat: 1 µl; mouse: 0.5 µl) of CCK-SAP (250 ng/µl) or Saporin (250 ng/µl) was injected at two sites rostral and caudal to the laryngeal nerve branch.

2010

See: Society for Neuroscience 2010 Abstracts

2009

Zhang W, Gardell S, Zhang D, Xie JY, Agnes RS, Badghisi H, Hruby VJ, Rance N, Ossipov MH, Vanderah TW, Porreca F, Lai J (2009) Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors. Brain 132:778-787. (Targeting Trends 09q3)

See also: Society for Neuroscience 2009 Abstracts

2008

See: Society for Neuroscience 2008 Abstracts

2006

Lai J, Zhang W, Badghisi H, Hruby VJ, Porreca F. (2006) The Biologically Active Cholecystokinin (26-33) peptide, [Tyr2-SO3]CCK-8, Retains High Affinity for CCK2 Receptors after Covalent Conjugation to Saporin. Targeting Trends 7(1).

2005

See: Society for Neuroscience 2005 Abstracts

2004

Porecca F, Hruby V, Lai J (2003) Targeting Tests: CCK-SAP in binding studies. Targeting Trends 4(3):5.

2003

Xie Y, Vanderah TW, Ossipov MH, Lai J, Porreca F (2003) A single rostral ventromedial medulla (RVM) treatment with cholecystokinin-saporin (CCK-SAP) prevents the development of opioid-induced paradoxical pain and spinal morphine antionociceptive tolerance. Soc Neurosci Mtg, New Orleans, LA, Abstract #177.4.

Zhang J, Speth RC, Simasko S, Ritter RC (2003) Hypothalamic injection of targeted toxin for cholecystokinin receptive neurons leads to increased 24 hour food intake and weight gain. Soc Neurosci Mtg, New Orleans, LA, Abstract #830.3.

Treece BR, Speth RC, Ritter RC, Burns GA (2003) Altered CCK binding in the dorsal vagal complex following cytotoxic lesion of the nodose ganglion. Soc Neurosci Mtg, New Orleans, LA, Abstract #830.5.